Haleon has completed a deal to boost its stake in its Chinese OTC joint venture, Tianjin TSKF Pharmaceutical.
The UK-based consumer health specialist has invested around £0.5bn ($0.6bn) to acquire an additional 33% equity interest in TSKF
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?